AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 9169397 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive insulin treatment (in predefined group without previous insulin treatment and low cardiovascular risk)
Number of subjects: 620
Study 9169397 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment (control group in predefined group without previous insulin treatment and low cardiovascular risk)
Number of subjects: 620
Study 1316404 — intervention group
Group type: EXPERIMENTAL
Intervention: Benazepril (10 mg)
Number of subjects: 8
Study 1316404 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 3921727 — intervention group
Group type: EXPERIMENTAL
Intervention: Abstinence from alcohol for six weeks, followed by resuming usual alcohol intake for five weeks.
Number of subjects: 24
Study 3921727 — intervention group
Group type: COMPARATOR
Intervention: Usual level of alcohol intake throughout the trial.
Number of subjects: 24
Study 3921727 — intervention group
Group type: EXPERIMENTAL
Intervention: Resuming alcohol intake after six weeks of abstinence.
Number of subjects: 24
Study 31931236 — intervention group
Group type: EXPERIMENTAL
Intervention: ΔSo2 (v - jv) on day 3 in nonsurvivor group
Number of subjects: 90
Study 31931236 — intervention group
Group type: EXPERIMENTAL
Intervention: ΔSo2 (v - jv) on day 3 in survivor group
Number of subjects: 90
Study 31931236 — intervention group
Group type: EXPERIMENTAL
Intervention: ΔSo2 (v - jv) on day 1 in nonsurvivor group
Number of subjects: 90
Study 31931236 — intervention group
Group type: EXPERIMENTAL
Intervention: ΔSo2 (v - jv) on day 1 and day 3 in unfavorable neurologic outcome group
Number of subjects: 90
Study 30819700 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrabrief intervention (UBI) with three structured appointments over 5 weeks.
Number of subjects: 160
Study 30819700 — intervention group
Group type: COMPARATOR
Intervention: Practice as usual (PAU) without UBI training.
Number of subjects: 160
Study 28361971 — intervention group
Group type: EXPERIMENTAL
Intervention: PG2 (500 mg, IV) administered 3 doses per week for 2 weeks
Number of subjects: 61
Study 28361971 — intervention group
Group type: COMPARATOR
Intervention: PG2 placebo
Number of subjects: 61
Study 25724233 — intervention group
Group type: EXPERIMENTAL
Intervention: STN DBS
Number of subjects: 0
Study 25724233 — intervention group
Group type: COMPARATOR
Intervention: GPi DBS
Number of subjects: 0
Study 23433461 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual antiplatelet therapy for 48 months (clopidogrel plus aspirin)
Number of subjects: 1966
Study 23433461 — intervention group
Group type: COMPARATOR
Intervention: Dual antiplatelet therapy for 12 months (clopidogrel plus aspirin)
Number of subjects: 1966
Study 20592662 — intervention group
Group type: EXPERIMENTAL
Intervention: Phentermine (abrupt cessation)
Number of subjects: 35
Study 20592662 — intervention group
Group type: COMPARATOR
Intervention: Amphetamine dependence (control group)
Number of subjects: 35
Study 20009826 — intervention group
Group type: EXPERIMENTAL
Intervention: Innervated free TRAM flap
Number of subjects: 27
Study 20009826 — intervention group
Group type: COMPARATOR
Intervention: Noninnervated free TRAM flap
Number of subjects: 27
Study 17111319 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderately intense activities (> 4 METs) for at least 210 min a week (4 M (210))
Number of subjects: 67
Study 17111319 — intervention group
Group type: EXPERIMENTAL
Intervention: More intense activities (> 6 METs) for at least 60 min a week (6 M (60))
Number of subjects: 67
Study 15098218 — intervention group
Group type: EXPERIMENTAL
Intervention: Nursing intervention
Number of subjects: 0
Study 15098218 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study 12577352 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy combined with Guben Yiliu III (GBYL)
Number of subjects: 81
Study 12577352 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy combined with moxibustion and Guben Yiliu III (GBYL)
Number of subjects: 81
Study 12577352 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone (Control group)
Number of subjects: 81
Study 9436636 — intervention group
Group type: EXPERIMENTAL
Intervention: CEOP‐Bleo regimen (cyclophosphamide, vincristine, epirubicin, prednisone and bleomycin)
Number of subjects: 169
Study 9436636 — intervention group
Group type: COMPARATOR
Intervention: CIOP‐Bleo regimen (idaurubicin instead of epirubicin)
Number of subjects: 169
Study 9436636 — intervention group
Group type: EXPERIMENTAL
Intervention: CEOP‐Bleo regimen
Number of subjects: 169
Study 9436636 — intervention group
Group type: COMPARATOR
Intervention: CIOP‐Bleo regimen
Number of subjects: 169
Study 8357509 — intervention group
Group type: EXPERIMENTAL
Intervention: Reach Wonder Grip toothbrush
Number of subjects: 68
Study 8357509 — intervention group
Group type: COMPARATOR
Intervention: Colgate Plus Junior toothbrush
Number of subjects: 68
Study 8357509 — intervention group
Group type: EXPERIMENTAL
Intervention: Preference questionnaire
Number of subjects: 68
Study 2427836 — intervention group
Group type: EXPERIMENTAL
Intervention: Celiprolol 200 mg
Number of subjects: 34
Study 2427836 — intervention group
Group type: EXPERIMENTAL
Intervention: Celiprolol 400 mg
Number of subjects: 34
Study 2427836 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study 2427836 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol 100 mg
Number of subjects: 34
Study 2427836 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol 40 mg
Number of subjects: 34
Study 2427836 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol 40 mg (pretreatment)
Number of subjects: 34
Study 2427836 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol and Propranolol
Number of subjects: 34
Study 2427836 — intervention group
Group type: EXPERIMENTAL
Intervention: Celiprolol
Number of subjects: 34
Study 2557481 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional amount of bicarbonate (33 +/- 2 mmol/liter) in the dialysate (Group A)
Number of subjects: 21
Study 2557481 — intervention group
Group type: COMPARATOR
Intervention: Higher amount of sodium bicarbonate (7 to 15 mmol/liter) added to the dialysate to obtain 24 mEq predialysis bicarbonate plasma levels (Group B)
Number of subjects: 21
Study 31413183 — intervention group
Group type: EXPERIMENTAL
Intervention: READY (n=53)
Number of subjects: 107
Study 31413183 — intervention group
Group type: COMPARATOR
Intervention: Control (n=54)
Number of subjects: 107
Study 27396432 — intervention group
Group type: EXPERIMENTAL
Intervention: Blanketing
Number of subjects: 28
Study 27396432 — intervention group
Group type: COMPARATOR
Intervention: Non-blanketing
Number of subjects: 28
Study 25187399 — intervention group
Group type: EXPERIMENTAL
Intervention: Bapineuzumab (6 doses intravenously once every 13 weeks)
Number of subjects: 1458
Study 23448278 — intervention group
Group type: EXPERIMENTAL
Intervention: GSK2239633 100 μg intravenous infusion
Number of subjects: 30
Study 23448278 — intervention group
Group type: COMPARATOR
Intervention: GSK2239633 150-1500 mg oral doses
Number of subjects: 30
Study 21503852 — intervention group
Group type: EXPERIMENTAL
Intervention: Dental loupes (2.5×, LED headlight)
Number of subjects: 22
Study 21503852 — intervention group
Group type: COMPARATOR
Intervention: No dental loupes
Number of subjects: 22
Study 18353720 — intervention group
Group type: EXPERIMENTAL
Intervention: Carperitide infusion (group II)
Number of subjects: 75
Study 18353720 — intervention group
Group type: COMPARATOR
Intervention: Nitroglycerin (group I)
Number of subjects: 75
Study 16507741 — intervention group
Group type: EXPERIMENTAL
Intervention: Active dissemination of the North American Guidelines for Children's Agricultural Tasks (NAGCAT)
Number of subjects: 0
Study 16507741 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 0
Study 14692210 — intervention group
Group type: EXPERIMENTAL
Intervention: Colgate Total Advanced Fresh toothpaste
Number of subjects: 0
Study 14692210 — intervention group
Group type: COMPARATOR
Intervention: Commercially available fluoride breath-freshening toothpaste
Number of subjects: 0
Study 10869261 — intervention group
Group type: EXPERIMENTAL
Intervention: Cariporide (40 mg intravenous bolus)
Number of subjects: 100
Study 10869261 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 9374084 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel 200 mg/m2 intravenously over 3 hours for eight cycles over 24 weeks
Number of subjects: 209
Study 9374084 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment with oral cyclophosphamide 100 mg/m2/d days 1 to 14, intravenous methotrexate 40 mg/m2 days 1 and 8, intravenous 5‐fluorouracil 600 mg/m2 days 1 and 8, and oral prednisone 40 mg/m2 daily days 1 to 14 (CMFP) for six cycles over 24 weeks
Number of subjects: 209
Study 1546547 — intervention group
Group type: EXPERIMENTAL
Intervention: Clomipramine (25‐75 mg; flexible dosage)
Number of subjects: 40
Study 1546547 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 1546547 — intervention group
Group type: EXPERIMENTAL
Intervention: Clomipramine
Number of subjects: 40
Study 2580694 — intervention group
Group type: EXPERIMENTAL
Intervention: Go stimuli (response production)
Number of subjects: 12
Study 2580694 — intervention group
Group type: EXPERIMENTAL
Intervention: No-Go stimuli (response inhibition)
Number of subjects: 12
Study 2580694 — intervention group
Group type: EXPERIMENTAL
Intervention: No-Go stimuli
Number of subjects: 12
Study 2580694 — intervention group
Group type: EXPERIMENTAL
Intervention: Counting Go stimuli
Number of subjects: 12
Study 2580694 — intervention group
Group type: EXPERIMENTAL
Intervention: Button pressing for Go stimuli
Number of subjects: 12
Study 29516192 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote ischaemic conditioning (RIC)
Number of subjects: 258
Study 29516192 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (SOC)
Number of subjects: 258
Study 27881106 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifamily therapy (MFT-AN)
Number of subjects: 169
Study 27881106 — intervention group
Group type: COMPARATOR
Intervention: Single family therapy (FT-AN)
Number of subjects: 169
Study 27881106 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 169
Study 25011421 — intervention group
Group type: EXPERIMENTAL
Intervention: SHED-IT intervention groups
Number of subjects: 159
Study 25011421 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 159
Study 22709755 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranolazine (1,000 mg twice daily for 7 days)
Number of subjects: 70
Study 22709755 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study 20833988 — intervention group
Group type: EXPERIMENTAL
Intervention: Low glycemic index (GI) dietary advice
Number of subjects: 104
Study 20833988 — intervention group
Group type: COMPARATOR
Intervention: Conventional carbohydrate exchange (CCE) dietary advice
Number of subjects: 104
Study 18280116 — intervention group
Group type: EXPERIMENTAL
Intervention: 100mg immediate-release (IR) tablets
Number of subjects: 48
Study 18280116 — intervention group
Group type: EXPERIMENTAL
Intervention: 250mg controlled-release (CR) tablets
Number of subjects: 48
Study 18280116 — intervention group
Group type: EXPERIMENTAL
Intervention: 500mg IR BID
Number of subjects: 48
Study 18280116 — intervention group
Group type: EXPERIMENTAL
Intervention: 1250mg CR QD
Number of subjects: 48
Study 18280116 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 15699835 — intervention group
Group type: EXPERIMENTAL
Intervention: Cessation of enteral tube feeding for RV >400 mL in study patients
Number of subjects: 40
Study 15699835 — intervention group
Group type: COMPARATOR
Intervention: Cessation of enteral tube feeding for RV >200 mL in controls
Number of subjects: 40
Study 15699835 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous endoscopic gastrostomy tubes
Number of subjects: 40
Study 15699835 — intervention group
Group type: COMPARATOR
Intervention: Nasogastric tubes
Number of subjects: 40
Study 15699835 — intervention group
Group type: EXPERIMENTAL
Intervention: RV <150 mL
Number of subjects: 40
Study 15699835 — intervention group
Group type: EXPERIMENTAL
Intervention: RV >400 mL
Number of subjects: 40
Study 15699835 — intervention group
Group type: EXPERIMENTAL
Intervention: RV >300 mL
Number of subjects: 40
Study 15699835 — intervention group
Group type: EXPERIMENTAL
Intervention: RV >200 mL
Number of subjects: 40
Study 15699835 — intervention group
Group type: EXPERIMENTAL
Intervention: RV >150 mL
Number of subjects: 40
Study 15699835 — intervention group
Group type: EXPERIMENTAL
Intervention: Blue food coloring detection
Number of subjects: 40
Study 12426766 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel drug delivery system with average particle size between 1-150 microns
Number of subjects: 0
Study 12426766 — intervention group
Group type: COMPARATOR
Intervention: Microemulsion system
Number of subjects: 0
Study 9504848 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative responses after vestibular nerve section
Number of subjects: 9
Study 9504848 — intervention group
Group type: COMPARATOR
Intervention: Preoperative responses
Number of subjects: 9
Study 9504848 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up responses
Number of subjects: 9
Study 7814484 — intervention group
Group type: EXPERIMENTAL
Intervention: Monovalent influenza A/Taiwan/1/86 (H1N1) virus HA, doses ranging from 0 to 405 micrograms per dose
Number of subjects: 139
Study 7814484 — intervention group
Group type: EXPERIMENTAL
Intervention: Trivalent HA vaccine containing A/H1N1, A/H3N2, and influenza B virus HA, doses ranging from 0 to 135 micrograms per strain, 0 to 405 micrograms per dose
Number of subjects: 139
Study 7814484 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 139
Study 7814484 — intervention group
Group type: COMPARATOR
Intervention: Standard dose of commercial influenza vaccine (control group)
Number of subjects: 139
Study 2528230 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive dynamic back extensor exercises (30 sessions over 3 months)
Number of subjects: 105
Study 2528230 — intervention group
Group type: COMPARATOR
Intervention: Alternative group with 1/5 of the treatment group's exercise program per session
Number of subjects: 105
Study 2528230 — intervention group
Group type: COMPARATOR
Intervention: Alternative group with thermotherapy, massage, and mild exercise
Number of subjects: 105
Study 29400990 — intervention group
Group type: EXPERIMENTAL
Intervention: Inspiratory muscle training (IMT) using a POWERbreathe KH1 device, commenced at 50% maximum inspiratory pressure, with training load progressively increased
Number of subjects: 7
Study 28611235 — intervention group
Group type: EXPERIMENTAL
Intervention: ivacaftor
Number of subjects: 20
Study 28611235 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 20
Study 27477305 — intervention group
Group type: EXPERIMENTAL
Intervention: OCT guided atherectomy with the Pantheris™ device
Number of subjects: 11
Study 23983130 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention-2 (point-of-care decision support and parent outreach)
Number of subjects: 549
Study 23983130 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 549
Study 21901266 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 set in lower-body exercises and 3 sets in upper-body exercises (1L-3UB)
Number of subjects: 15
Study 21901266 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 sets in lower-body exercises and 1 set in upper-body exercises (3L-1UB)
Number of subjects: 15
Study 21901266 — intervention group
Group type: EXPERIMENTAL
Intervention: Training (both groups)
Number of subjects: 15
Study 19874925 — intervention group
Group type: EXPERIMENTAL
Intervention: AMA1-C1/Alhydrogel + CPG 7909
Number of subjects: 24
Study 19874925 — intervention group
Group type: COMPARATOR
Intervention: AMA1-C1/Alhydrogel
Number of subjects: 24
Study 17803844 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine + Zolpidem (Group A, treated with paroxetine 10 ‐ 20 mg/d and zolpidem 10 mg/d for 4 weeks)
Number of subjects: 229
Study 17803844 — intervention group
Group type: COMPARATOR
Intervention: Paroxetine only (Group B)
Number of subjects: 229
Study 15149563 — intervention group
Group type: EXPERIMENTAL
Intervention: FSH-mass
Number of subjects: 250
Study 15149563 — intervention group
Group type: COMPARATOR
Intervention: FSH-bio
Number of subjects: 250
Study 12139731 — intervention group
Group type: EXPERIMENTAL
Intervention: UKALL XI protocol with two 5‐d intensification blocks at 5 and 20 weeks and a third intensification at 35 weeks.
Number of subjects: 3617
Study 12139731 — intervention group
Group type: EXPERIMENTAL
Intervention: UKALL XI protocol
Number of subjects: 3617
Study 12139731 — intervention group
Group type: COMPARATOR
Intervention: UKALL X protocol
Number of subjects: 3617
Study 12139731 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased intensity of therapy
Number of subjects: 3617
Study 12139731 — intervention group
Group type: EXPERIMENTAL
Intervention: Introduction of a third late intensification block
Number of subjects: 3617
Study 9839627 — intervention group
Group type: EXPERIMENTAL
Intervention: Intralesional hyaluronidase (HD) pretreatment
Number of subjects: 9
Study 8074012 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhalation of cold air (−22 degrees C) during exercise
Number of subjects: 10
Study 8074012 — intervention group
Group type: COMPARATOR
Intervention: Inhalation of thermoneutral air (22 degrees C) during exercise
Number of subjects: 10
Study 2520633 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed-loop control system (CLCS)
Number of subjects: 45
Study 2520633 — intervention group
Group type: COMPARATOR
Intervention: Manual control
Number of subjects: 45
Study 2520633 — intervention group
Group type: COMPARATOR
Intervention: Computer-assisted control
Number of subjects: 45
Study 766497 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifurantin
Number of subjects: 0
Study 766497 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulfaclomid
Number of subjects: 0
Study 766497 — intervention group
Group type: EXPERIMENTAL
Intervention: Target therapy as per antibiogram
Number of subjects: 0
Study 766497 — intervention group
Group type: EXPERIMENTAL
Intervention: Blind early therapy with Nifurantin
Number of subjects: 0
Study 766497 — intervention group
Group type: EXPERIMENTAL
Intervention: Simultaneous urine culture
Number of subjects: 0
Study 31375458 — intervention group
Group type: EXPERIMENTAL
Intervention: Equation2 for active subjects: 33.08 + 2.41*(Velfinal) - 0.32*(F%) + 0.40*(VE_VT‐II) - 0.26*(BM) - 0.09*(HR_VT‐II)
Number of subjects: 181
Study 31375458 — intervention group
Group type: EXPERIMENTAL
Intervention: Equation3 for sedentary subjects: 54.65 + 1.37*(T_VT‐II) + 8.24*(sex) - 1.26*(BMI) + 0.37*(VE_VT‐II) - 0.12*(HR_VT‐II)
Number of subjects: 181
Study 31603939 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous vagus nerve stimulation at different intensities (0.5, 1.0, 1.5 mA)
Number of subjects: 61
Study 31603939 — intervention group
Group type: EXPERIMENTAL
Intervention: Set stimulation method
Number of subjects: 61
Study 31603939 — intervention group
Group type: EXPERIMENTAL
Intervention: Free stimulation method
Number of subjects: 61
Study 31603939 — intervention group
Group type: EXPERIMENTAL
Intervention: Active stimulation
Number of subjects: 61
Study 31603939 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 61
Study 31603939 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher stimulation intensities
Number of subjects: 61
Study 28355926 — intervention group
Group type: EXPERIMENTAL
Intervention: Couple HIV testing and counseling (cHTC) attendance
Number of subjects: 200
Study 28355926 — intervention group
Group type: EXPERIMENTAL
Intervention: Male partner ART reminders
Number of subjects: 200
Study 28355926 — intervention group
Group type: EXPERIMENTAL
Intervention: Early disclosure of HIV-positive status
Number of subjects: 200
Study 28355926 — intervention group
Group type: EXPERIMENTAL
Intervention: cHTC attendance among retained women
Number of subjects: 200
Study 25781525 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 22
Study 25781525 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral Contraceptive Pills (OCP)
Number of subjects: 22
Study 25781525 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 22
Study 23816952 — intervention group
Group type: COMPARATOR
Intervention: Inhalation of 0% CO2
Number of subjects: 0
Study 23816952 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhalation of 9% CO2
Number of subjects: 0
Study 23816952 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhalation of 17.5% CO2
Number of subjects: 0
Study 23816952 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhalation of 35% CO2
Number of subjects: 0
Study 23816952 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhalation of CO2 (all concentrations)
Number of subjects: 0
Study 21414600 — intervention group
Group type: EXPERIMENTAL
Intervention: Final kissing balloon (KB) inflation, n = 124
Number of subjects: 293
Study 21414600 — intervention group
Group type: COMPARATOR
Intervention: Isolated balloon after dilation (non-KB), n = 120
Number of subjects: 293
Study 19290717 — intervention group
Group type: EXPERIMENTAL
Intervention: Personality disorder indication
Number of subjects: 268
Study 19290717 — intervention group
Group type: EXPERIMENTAL
Intervention: Social support
Number of subjects: 268
Study 19290717 — intervention group
Group type: EXPERIMENTAL
Intervention: Grief severity
Number of subjects: 268
Study 19290717 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV symptoms
Number of subjects: 268
Study 17005526 — intervention group
Group type: EXPERIMENTAL
Intervention: pH neutral, lactate-buffered, low GDP solution (balance)
Number of subjects: 50
Study 17005526 — intervention group
Group type: COMPARATOR
Intervention: Conventional lactate‐buffered fluid (control)
Number of subjects: 50
Study 15021447 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene (RAL) 60 mg/day
Number of subjects: 50
Study 15021447 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 50
Study 11710752 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous hydrocortisone (0, 25, 50, 100 or 200 mg)
Number of subjects: 4
Study 9278796 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical diclofenac
Number of subjects: 20
Study 9278796 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 20
Study 2036070 — intervention group
Group type: EXPERIMENTAL
Intervention: Madopar HBS (sustained-release preparation)
Number of subjects: 9